Propelled By Growing Geriatric Population Suffering From Gout Disease The Global Gout Disease Treatment Market Is Estimated To Be Valued At US$ 3.01 Bn In 2023

by

Gout disease treatment focuses on reducing uric acid levels in the bloodstream with medications such as allopurinol and febuxostat. The condition commonly strikes men over the age of 40 and post-menopausal women. As life expectancy rises globally, the aged population prone to gout is expanding rapidly. The global Gout Disease Treatment Market is estimated to be valued at US$ 3.01 Bn in 2023 and is expected to exhibit a CAGR of 9.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Growing rates of obesity andassociated diseases like diabetes and hypertension have contributed significantly to the rising prevalence of gout. As overweight people are more at risk of developinghyperuricemiaor high uric acid levels in the blood, their odds of experiencing gout flares are greater too. This key trend has therefore augmented the market demand for gout treatments across developed nations with a heavy disease burden of obesity. novel drug research continues to explore more effective therapeutic strategies for long-term gout management in overweight individuals.
SWOT Analysis
Strength: Gout disease treatment drugs like febuxostat and pegloticase are effective in treating acute gout attacks and hyperuricemia.
Weakness: High cost of biologic therapy for gout along with side effects associated with long term usage of drugs which include liver toxicity, cardiovascular risk etc.
Opportunity: Increasing research and development in targeted therapies and development of drugs with improved efficacy and safety profiles.
Threats: Generic competition once key drug patents expire can significantly reduce prices of branded gout drugs. Stringent regulatory pathways for approval of new drugs.

Key Takeaways
The global gout disease treatment market is expected to witness high growth. Regional analysis related content comprises Regional analysis related content

The global gout disease treatment market size is dominated by North America. Factors such as high prevalence of gout and hyperuricemia, high healthcare spending, favorable reimbursement policies for gout drugs drive the North America gout disease treatment market. Europe is the second largest market globally due to growing awareness about gout management. Meanwhile, Asia Pacific region is expected to witness rapid growth owing to expanding patient base, improving access to diagnosis and treatment., growing healthcare expenditure.

Key players operating in the gout disease treatment market are Kerry Group plc, Takasago International Corporation, Sensient Technologies Corporation, Symrise AG, Givaudan SA, Firmenich International SA, Frutarom Industries Ltd., Citromax Flavors, Inc., and International Flavors & Fragrances Inc. These companies are focused on extensive research and development activities to develop novel therapies for effective treatment of gout. In addition, they adopt strategies such as collaborations, acquisitions and regulatory approvals to strengthen their market position.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it

Ravina
+ posts

Ravina Pandya,  Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.